Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group

NCT04121455 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT04121455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group
Lead sponsor
TME Pharma AG
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 12, 2019
Completion date
December 31, 2028
Enrollment
117 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma